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Abstract: Sustained HER2/HER3 signaling due to the overproduction of the HER3 ligand heregulin 
(HRG) is proposed as a key contributor to endocrine resistance in estrogen receptor-positive (ER+) 
breast cancer. The molecular mechanisms linking HER2 transactivation by HRG-bound HER3 to the 
acquisition of a hormone-independent phenotype in ER+ breast cancer is, however, largely 
unknown. Here, we explored the possibility that autocrine HRG signaling drives cytokine-related 
endocrine resistance in ER+ breast cancer cells. We used human cytokine antibody arrays to semi-
quantitatively measure the expression level of 60 cytokines and growth factors in the extracellular 
milieu of MCF-7 cells engineered to overexpress full-length HRGβ2 (MCF-7/HRG cells). Interleukin-
8 (IL-8), a chemokine closely linked to ER inaction, emerged as one the most differentially expressed 
cytokines. Cytokine profiling using structural deletion mutants lacking both the N-terminus and the 
cytoplasmic-transmembrane region of HRGβ2—which is not secreted and cannot transactivate 
HER2—or lacking a nuclear localization signal at the N-terminus—which cannot localize at the 
nucleus but is actively secreted and transactivates HER2—revealed that the HRG-driven activation 
of IL-8 expression in ER+ cells required HRG secretion and transactivation of HER2 but not HRG 
nuclear localization. The functional blockade of IL-8 with a specific antibody inversely regulated 
ERα-driven transcriptional activation in endocrine-sensitive MCF-7 cells and endocrine-resistant 
MCF-7/HRG cells. Overall, these findings suggest that IL-8 participates in the HRG-driven 
endocrine resistance program in ER+/HER2- breast cancer and might illuminate a potential clinical 
setting for IL8- or CXCR1/2-neutralizing antibodies. 
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1. Introduction 
The estrogen receptor (ER) is expressed in ~75% of breast carcinomas and is a key molecular 
driver and therapeutic target in these ER-positive (ER+) tumors [1]. Clinically, patients with ER+ 
breast cancer are treated with either selective ER modulators such as tamoxifen, which binds to and 
blocks ER, or selective estrogen degraders such as fulvestrant, which binds ER and induces its 
proteasomal degradation. Aromatase inhibitors, which lower the levels of estrogen by inhibiting the 
enzymatic conversion of androgens to estrogens, are typically employed as a second line of treatment 
in tamoxifen-resistant tumors. Despite the well-known ability of adjuvant endocrine therapy to 
prolong disease-free and overall survival in ER+ breast cancer, tumors in more than 50% of patients 
with metastases fail to respond, and nearly all metastatic and initially responsive tumors ultimately 
show tumor relapse due to acquired resistance [2–7]. One of the most predominant mechanisms of 
resistance to endocrine therapy in ER+ breast cancer is the cross-talk between ER and growth factor 
receptor pathways, which facilitates a transition from ligand (E2)-dependent to ligand-independent 
ER activation, ultimately leading to a reprogrammed ER transcriptional activity. Unfortunately, most 
of the intermediate molecular conduits linking growth factor receptor pathways to ER transcriptional 
reprogramming that promote endocrine-resistant breast cancer remain poorly understood. 
Gene set enrichment analyses have revealed that ligand-induced transactivation of the human 
epidermal growth factor receptor 2 (HER2) or other members of the EGFR family in HER2-negative 
tumors generates an overlapping gene signature to that of the highly proliferative luminal-B subtype 
of ER+ breast carcinomas [8]. Indeed, HER-activating growth factors appear to contribute 
significantly to the endocrine-resistant phenotype, underpinning the poor clinical outcome of 
luminal-B tumors treated with tamoxifen. A clinical study examining a large retrospective group of 
tamoxifen-treated patients with ER+ breast cancer revealed that HER1+/HER3+ patients were 
significantly more likely to relapse on tamoxifen [9]. In addition, tamoxifen-sensitive luminal-like 
breast cancer cells exogenously treated with the HER3 ligand HRGβ1, or engineered to overproduce 
the HER3 ligand HRGβ2, have been shown to acquire a bona fide endocrine-resistant phenotype in 
terms of estrogen-independent growth and refractoriness to anti-estrogen therapies, both in vitro and 
in vivo [10–15]. Beyond the overlapping downstream activation of PI3K/AKT and MAPK signaling 
cascades present in ER+ breast cancer cells overexpressing HER2 [16–18], which also acquire an 
endocrine-resistant phenotype, the definitive mechanisms linking HER2 transactivation by HRG-
bound HER3 to the acquisition of a hormone-independent phenotype in ER+ breast cancer cells are 
largely unknown. 
Both the quantitative and qualitative repertoire of autocrine and paracrine cytokines are 
emerging as potential contributors to the metastatic and therapy-resistant phenotype of breast cancer 
in an ER-related manner. For instance, interleukin-8 (IL-8/ CXCL8), a prototypical member of a 
superfamily of small, inducible secreted CXC chemokines, is positively associated with invasiveness 
and angiogenic and metastatic potential in breast cancer cells and is negatively linked to ER status 
[19–26]. Here, we explored the possibility that autocrine HRG signaling drives cytokine-mediated 
endocrine resistance in ER+ breast cancer cells. Using cytokine antibody array technology [21,27] and 
structural HRG mutants with specifically altered capacities to be secreted and transactivate HER2 
[28,29], we provide phenotypic and mechanistic evidence that IL-8 might operate as an enabling 
factor promoting estrogen-independency and anti-estrogen resistance in HRG-overexpressing ER-
positive/HER2-negative breast carcinoma cells. 
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2. Results 
2.1. Identification of IL-8 as an HRG-Driven Cytokine Using Chemokine Antibody Array Technology 
We used human cytokine antibody array analysis to identify differential HRG-driven cytokine 
responses in ER+ breast cancer cells. Using the RayBio™ (Norcross, GA, USA) C-series (C7) Human 
Cytokine Array, we simultaneously screened the expression of 60 different cytokines, chemokines, 
growth factors, angiogenic factors, and proteases (Figure S1) in a conditioned medium from luminal 
A-like MCF-7 breast cancer cells engineered to overexpress either the full-length version of HRGβ2 
[28] or structural deletion mutants lacking specific domains that drive the extracellular versus nuclear 
localization of HRGβ2 [29] (Figure 1A). Specifically, the HRG-M4 structural mutant lacks both the 
nuclear localization signal (NLS) at the N-terminus and the cytoplasmic-transmembrane region of 
HRG, thereby generating a cytoplasm-restricted version that cannot be secreted and cannot 
transactivate HER2. The HRG-M1 structural mutant exclusively lacks the NLS at the N-terminus, 
thereby impairing the ability of HRG to localize in the nuclei of breast cancer cells. In contrast to 
HRG-M4, HRG-M1 can be secreted into the extracellular milieu and can effectively induce 
transactivation phenomena with HER2 (Figure 1A). 
 
Figure 1. Autocrine heregulin up-regulates IL-8 in luminal breast cancer cells. (A) Left. Schematic 
representation of the structural heregulin (HRG) mutants employed. Right. Forty-eight-hour 
conditioned media from MCF-7/pBABE, MCF-7/HRG, MCF-7/HRG-M1, and MCF-7/HRG-M4 cells 
were assayed for cytokine content as described in the “Materials and methods” section. Shown are 
representative results (n = 3) revealing conspicuous changes in uPAR, amphiregulin, and IL-8 secreted 
from MCF-7/HRG cells as compared with MCF-7/pBABE control counterparts. (B) IL-8 concentration 
in conditioned media from MCF-7/pBABE, MCF-7/HRG, MCF-7/HRG-M1, and MCF-7/HRG-M4 cells 
was assessed by ELISA. Values represent mean (columns) ± S.D. (bars) from three independent 
experiments. (**p < 0.005; n.s. not statistically significant). 
Figure 1A also shows the raw data images from the cytokine antibody array using MCF-
7/pBABE (control), MCF-7/HRG, MCF-7/HRG-M1, and MCF-7/HRG-M4 cells. Densitometric 
analyses suggested a slight elevation in the secretion of the urokinase-type plasminogen activator 
receptor (uPAR) and the EGFR (HER1) ligand amphiregulin in response to HRGβ2 overexpression 
in MCF-7/HRG cells. MCF-7/HRG cells further showed a noteworthy up-regulation of IL-8. MCF-
7/HRG-M1 cells generated a similar cytokine profile to that of MCF-7/HRG cells, which was 
characterized by the conspicuous up-regulation of IL-8. By contrast, MCF-7/HRG-M4 cells failed to 
up-regulate IL-8, but did show an up-regulation of uPAR and amphiregulin secretion. Quantitative 
determination of IL-8 levels by enzyme-linked immunosorbent assay (ELISA) confirmed the semi-
quantitative array data (Figure 1B). Specifically, MCF-7/pBABE control cells secreted 131 ± 14 pg IL-
8 mg protein-1, whereas MCF-7/HRG, MCF-7/HRG-M4, MCF-7/HRG-M1 cells expressed 440 ± 10, 87 
± 14, and 472 ± 19 pg IL-8 mg−1, respectively. 
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2.2. HRG Overexpression in HER2-Negative Breast Cancer Cells Qualitatively Phenocopies the IL-8 
Cytokine Signature Driven by her2 Overexpression 
Using the antibody-based RayBio™ (Norcross, GA, USA) Human Cytokine Array III, which 
simultaneously detects 42 cytokines and growth factors on one membrane, we previously 
demonstrated that HER2 overexpression in MCF-7 cells robustly up-regulated the expression of IL-8 
and the alpha-isotype of the growth-related oncogene (GRO; CXCL1) chemokine [27]. To test whether 
the HRG-driven cytokine signature was merely a phenocopy of that promoted by HER2 
overexpression, we re-screened the conditioned medium of MCF-7/Her2-18 transfectants with the 
RayBio™ (Norcross, GA, USA) C-series (C7) Human Cytokine Array. MCF-7/Her2-18 cells 
overexpress full-length HER2 cDNA under the control of the SV40 promoter and accumulate ~45-
times the level of HER2 protein of parental MCF-7 cells [16]. Similar to MCF-7/HRG cells, MCF-
7/Her2-18 cells notably augmented the secretion of uPAR, amphiregulin and, particularly, IL-8, when 
compared with MCF-7/neo control counterparts (Figure 2A). In contrast to MCF-7/HRG cells, 
however, MCF-7/Her2-18 cells also showed an elevated secretion of TIMP-2, VEGF, and GRO relative 
to control cells. Although qualitatively similar in terms of IL-8 expression, when compared with 
MCF-7/pBABE and MCF-7/neo control cells, quantitative analysis of extracellular IL-8 levels by 
ELISA revealed a 12-fold increase in IL-8 secretion from MCF-7/Her2-18 cells, but only a 3.6-fold 
increase in MCF-7/HRG cells (Figure 2A). 
 
Figure 2. (A) HRG- and HER2-induced cytokine signatures are similar but not identical. Left. Forty-
eight-hour conditioned media from MCF-7/neo and MCF-7/Her2-18 cells were assayed for cytokine 
content as described in the “Materials and methods” section. Shown are representative results (n = 3) 
revealing conspicuous changes in TIMP-2, uPAR, VEGF, amphiregulin, GRO, and IL-8 secreted from 
MCF-7/Her2-18 cells as compared with MCF-7/neo control counterparts. Right. IL-8 concentration in 
conditioned media from MCF-7/neo and MCF-7/Her2-18 cells was assessed by ELISA. Values 
represent mean (columns) ± S.D. (bars) from three independent experiments. (**p < 0.005). (B) 
Suppression of HRG overexpression is not sufficient to down-regulate IL-8 overexpression in ER-
negative breast cancer cells. Forty-eight-hour conditioned media from HRG-/IL8-overexpressing 
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MDA-MB-231/AS-V cells and the HRG-negative MDA-MB-231/AS-31 clone were assayed for cytokine 
content as described in the “Materials and methods” section. Shown are representative results (n = 3) 
revealing conspicuous changes in TIMP-2, uPAR, VEGF, and IL-8 secreted from MDA-MB-231/AS-31 
cells as compared with MDA-MB-231/AS-V control counterparts. IL-8 concentration in conditioned 
media from MCF-7, MDA-MB-231/AS-V, and MDA-MB-231/AS-31 cells was assessed by ELISA. 
Values represent mean (columns) ± S.D. (bars) from three independent experiments. (*p < 0.05; **p < 
0.005). 
2.3. HRG-Driven Regulation of IL-8 Is ER-Dependent 
IL-8 is preferentially secreted in ER-negative breast cancer cells; indeed, no ER+ breast cancer 
cell line tested thus far has been found to express detectable levels of IL-8 [19–21]. Moreover, 
exogenous ER expression down-regulates IL-8 expression in ER-negative MDA-MB-231 cells, 
naturally overexpressing IL-8. Our finding that HRG overexpression in an ER+ background suffices 
to up-regulate IL-8 suggested the occurrence of a specific scenario of HRG-driven IL-8 
overproduction in ER-positive/HER2-negative breast cancer cells. To test this, we employed MDA-
MB-231 cells, a cancer cell line that naturally overexpresses HRGβ2 and IL-8, and a clonal derivative 
of this cell line stably transfected with an antisense HRGβ2 construct (MDA-MB-231/AS-31) [30], 
leading to almost undetectable HRGβ2 expression [30–33]. We thus characterized the cytokine 
signature of MDA-MB-231/AS-31 cells as an engineered model of ER-negative/HRG-negative breast 
cancer cells. Our results showed that whereas the blockade of HRG expression slightly decreased the 
amounts of secreted TIMP-2, uPAR, and VEGF in MDA-MB-231 cells, as determined with the 
RayBio™ (Norcross, GA, USA) C-series (C7) Human Cytokine Array, IL-8 overexpression become 
even more conspicuous in MDA-MB-231/AS-31 cells (Figure 2B). Specifically, ELISA determination 
of IL-8 levels confirmed a small but significant (35%) increase in secreted IL-8 in MDA-MB-231/AS-
31 cells as compared with MDA-MB-231/AS-V (vector control) counterparts (Figure 2B). 
2.4. Functional Blockade of IL-8 Regulates ER Transcriptional Activity in an HRG-Dependent Manner 
To evaluate the effects of functional blockade of IL-8 on ER-transactivation and E2 
responsiveness, we co-transfected MCF-7/pBABE and MCF-7/HRG cells with a Luciferase reporter 
gene linked to an Estrogen Response Element (ERE-Luciferase) and also with the internal control 
vector pRL-CMV. Transfected cells were then evaluated for changes in the levels of basal (E2-
independent) reporter activity in the presence of increasing concentrations of an anti-IL-8 antibody 
(Figure 3). 
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Figure 3. Blockade of IL-8 bioactivity differentially regulates ER-driven transcriptional activity in an 
HRG-dependent manner. (A) MCF-7/pBABE (top) and MCF-7/HRG (bottom) cells were transiently 
co-transfected with an ERE-Luciferase reporter (the ERE-containing reporter plasmid) and pRL/CMV 
(an internal reporter plasmid to control for transfection efficiency). Cells were incubated for 24 h in 
the absence or presence of vehicles (control), E2 and anti-IL-8 antibody individually or in the 
combinations specified, and cell extracts were analyzed for Luciferase activity. Data shown represent 
mean (columns) ± S.D. (bars) (n = 3). (B) E2-independent and E2-induced ER transcriptional activity 
following normalization intra- (top) and inter-normalization (bottom) to the activity of pRL-CMV 
(1.0-fold). (*p < 0.05; **p < 0.005) 
In the absence of E2, the basal transcriptional activity of the ER reporter was increased in a dose-
dependent manner in MCF-7/pBABE cells by treatment with an anti-IL-8 antibody, relative to 
untreated control cells (Figure 3A, top). Specifically, ER-dependent luciferase activation was 
increased 3.7-, 6.3- and 13.1-fold in the presence of 1, 5, and 10 μg/mL of anti-IL-8 antibody, 
respectively. We then transiently transfected MCF-7/pBABE cells with the ERE-Luciferase construct 
as before and treated them with a combination of E2 and anti-IL-8 antibody to determine whether 
their actions were additive, synergistic, or antagonistic. As a single agent, E2 (10−9 mol/L) induced a 
~5-fold increase in Luciferase activity relative to basal levels in untreated cells (Figure 3A, top). 
Remarkably, co-exposure of MCF-7/pBABE cells to E2 and anti-IL-8 antibody resulted in a dose-
dependent increase (up to ~70-fold at 10 μg/mL) in ERE-reporter activity (Figure 3A, top), 
representing a ~12-fold increase in ERα-dependent transcriptional activity when compared to the 
activity in E2-stimulated MCF-7/pBABE cells. Accordingly, the concentration of anti-IL8 antibody to 
produce a half-maximal effect was notably lower in the presence of E2 (~1 g/mL) than in its absence 
(~5 μg/mL). 
A completely different picture emerged when the impact of IL-8 blockade on ER transcriptional 
activity was measured in MCF-7/HRG cells using the same protocol. In the absence of E2 stimulation, 
we failed to observe any significant ER activation and instead observed a slight inhibition of the ER 
transcriptional activity in response to the functional blockade of IL-8 (Figure 3A, bottom). Such dose-
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dependent inhibitory behavior of ER transcriptional activity observed at the higher doses of the anti-
IL8 antibody was unaffected by the presence of E2. Accordingly, the dose of anti-IL8 antibody 
required to produce a 50% reduction of the maximum effect did not significantly vary between E2-
independent (~5 μg/mL) and E2-stimulated (~4 μg/mL) conditions. Indeed, the ability of the anti-IL-
8 antibody to decrease the E2-independent and E2-induced transcriptional activity of ER was more 
noticeable when the fold-increase in the ERE activity of MCF-7/HRG cells was inter-normalized to 
the ERE activity in MCF-7/pBABE cells (Figure 3B). 
3. Discussion 
Here, we explored the possibility that autocrine HRG signaling drives cytokine-related 
endocrine resistance in ER+ breast cancer cells. Analysis of the secreted “cytokine signature” in the 
extracellular milieu of luminal-like ER+ breast cancer cells exhibiting an HRG-driven endocrine-
resistant phenotype revealed the differential upregulation of three well-known regulators of ER 
activity, namely, uPAR, amphiregulin, and IL-8. The transition in uPAR signaling from transient and 
uPA-dependent to sustained and autonomous provides a selective advantage for ER+ breast cancer 
cells in the absence of E2, thereby serving as an escape pathway for breast cancer cells from ER-
targeting therapeutics equivalent to that provided by HER2 overexpression [34]. The epidermal 
growth factor receptor (EGFR/HER1) ligand amphiregulin is a key effector of ERα activity. Whereas 
endocrine therapy induces suppression of amphiregulin in responsive cells, the activation of an 
amphiregulin/EGFR autocrine loop has been proposed to drive endocrine-resistant phenotypes in 
breast cancer [35–37]. The synthesis and secretion of IL-8 in breast cancer cells are known to closely 
relate to ER status [19–26]; IL-8 secretion is apparently low in ER-positive breast cancer cell lines and 
tends to be high in ER-negative cells. Autocrine production of IL-8 is inversely associated with cancer 
cell responses to tamoxifen, and tamoxifen-resistant derivative cells exhibit elevated IL-8 expression, 
thereby suggesting that IL-8 could also be a cause and indicator of endocrine resistance as a part of 
the IL-8-mediated program of metastatic progression of breast cancer [19–26]. Using structural 
mutants of HRG with altered capacities to distribute throughout intracellular versus extracellular 
compartments, we found that IL-8, but not uPAR or amphiregulin, was the sole trait of the HRG-
driven “cytokine signature” involving autocrine signaling, leading to sustained transactivation of 
HER2. 
HRG-driven activation of IL-8 expression in ER+ cells was found to require HRG secretion and 
transactivation of HER2, but not HRG nuclear localization. The occurrence of self-sustaining 
autocrine signaling of HRG might, therefore, suffice to establish a positive link between IL-8 
expression, ERα activity, and endocrine therapy responsiveness independently of HER2 
overexpression. Indeed, our findings might add a new dimension to the ongoing controversy 
regarding ER/IL-8 cross-talk, namely, the inverse correlation between IL-8 expression with ER status 
(i.e., ER downregulates IL-8 expression independently of estradiol) and the positive correlation 
between estradiol and IL-8 (i.e., estradiol seems to augment IL-8 expression). On the one hand, the 
ability of HRG to up-regulate IL-8 expression cannot be established in the absence of ER [19,20]. 
Accordingly, the IL-8-overexpressing phenotype of ER-negative MDA-MB-231 remained unaffected 
upon the silencing of HRG. On the other hand, IL-8 might affect the endocrine responsiveness of ER-
positive breast cancer cells through modulation of ER activity. When we tested whether IL-8 could 
alter the transcriptional activity of Erα, we found that incubation of ER+/HRG-negative breast cancer 
cells with an antibody against IL-8 triggered a dramatic, dose-dependent increase in ER 
transcriptional activity in endocrine-responsive cells, which was more pronounced when combined 
with E2. It should be noted that blockade of IL-8 was sufficient to activate ERα transcriptional activity 
and that the magnitude of the activation by the combination of the anti-IL-8 antibody and E2 was far 
greater than the naturally saturated response of ligand (E2)-occupied ERα in low-IL-8-expressing 
breast cancer cells. These observations, together with the fact that the direction of the effects of IL-8 
targeting on ERα transcriptional activity switched in an HRG-dependent manner, support a possible 
mechanistic framework where IL-8 might operate as a corepressor for ERα itself by directly 
controlling ERα activity or, alternatively, by activating one or several intermediary ERα corepressing 
Int. J. Mol. Sci. 2020, 21, 7737 8 of 15 
mechanisms such as expression/activity of chromatin remodelers, competition with ERα coactivators, 
or alteration of ERα protein stability, among others [38–46]. 
HRG-induced formation of HER2/HER3 heterodimers—which are considered the most potent 
pairs with respect to the strength of interaction, ligand-induced tyrosine phosphorylation, and 
downstream signaling—will enhance IL-8 expression downstream of overactive MAPK and PI3K 
signaling pathways, whereas autocrine signaling of IL-8 via its CXCR1/2 receptor will enhance and 
prolong further HER2/HER3-mediated signaling [47–49]. Thus, in HRG-overexpressing ER+/HER2-
negative cells, specific neutralization of IL-8 bioactivity likewise reduces the ability of HRG 
overexpression to increase the non-genomic (e.g., MAPK- and PI3K-induced) unliganded 
transcriptional activity of ERα. The finding that anti-IL-8 treatment reduced but did not completely 
block the E2-independent hyperactivity of ER in the continuous presence of up-stream oncogenic 
stimuli such as HRG suggests a need not only for combined treatment with drugs capable of 
impeding ligand-induced HER2/HER3 signaling (e.g., pertuzumab) but also the potential 
involvement of additional HRG-driven ERα co-activating cytokines (e.g., IL6, which is known to be 
repressed by E2-driven activation of ERα but drives endocrine therapy resistance by various 
mechanisms including direct transcriptional activation of ERα [50–56]). In this complex scenario of 
multiple cytokines driving endocrine resistance in HRG-overexpressing ER+ breast cancer cells, the 
sole blockade of IL-8 bioactivity might become inadequate in the presence of an augmented 
availability of IL-6 downstream of the HRG-activated HER2/HER2 oncogenic unit. Nonetheless, 
HRG/HER2:HER3-induced autocrine secretion of IL-8 can be viewed as part of the endocrine 
resistance program in HRG-overexpressing ER+ breast cancer cells by controlling the magnitude of 
the estrogen response and mediating the anti-estrogen inhibition of ERα [57]. Therefore, it is, 
tempting to suggest that IL-8 might be part of a context (HRG)-dependent regulatory mechanism that 
dictates endocrine responsiveness in ER+/HER2-negative breast cancer cells (Figure 4). In the absence 
of sustained HER2:HER3 signaling, blockade of such negative feedback will promote an exacerbated 
ERα transcriptional activation. In the presence of persistent HRG-induced activation of HER2:HER3 
signaling, the resulting augmentation of IL-8 secretion will further potentiate the non-genomic (e.g., 
MAPK- and PI3K-driven) potentiation of the unliganded transcriptional activity of ERα (e.g., via 
transactivation of HER2 [58,59]) characteristic of the endocrine-resistant phenotype in HRG-
overexpressing ER+ breast cancer cells. Intriguingly, the “cytokine events” driven by sustained HRG-
induced transactivation of HER2 via HER2/HER3 heterodimers were similar but not identical to those 
promoted by high levels of HER2 homodimers in HER2-overexpressing breast cancer cells. Whether 
the different signaling output dictated by the oligomeric conformations of HER2 in HRG-
positive/HER2-negative and HRG-negative/HER2-positive breast cancer cells [60] might explain the 
partial overlap between their respective cytokine signatures will require further investigation. 
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Figure 4. IL-8 participates in the HRG-driven endocrine resistance program in ER+ breast cancer cells. 
The regulatory actions of IL-8 on ER signaling can be related to the HER2:HER3-regulated stage of 
endocrine responsiveness. In the absence of persistent HER2:HER3 signaling, IL-8 expression might 
be part of a negative-feedback regulatory mechanism to fine-tune ER signaling. Accordingly, 
blockade of such negative feedback leads to exacerbated ERα transcriptional activation in response 
to E2. Autocrine HRG-induced heterodimerization and activation of HER2/HER3 stimulate the up-
regulation of IL-8 expression and secretion, which in turn might further potentiate the non-genomic 
(e.g., MAPK- and PI3K-driven) unliganded transcriptional activity of ER characteristic of the 
endocrine-resistant phenotype in ER+ breast cancer cells. 
It has been postulated that the net effect of IL-8 action in breast cancer progression involves a 
balance between the promotion of ER inaction and the occurrence of HER2 overexpression. 
Accordingly, IL-8 overexpression is characteristic of basal-like (ER-negative) and HER2-enriched 
(HER2+) intrinsic subtypes of breast carcinomas. However, the putative significance of IL-8 in ER-
positive/HER2-negative breast carcinomas has remained largely unexplored. Because IL-8, through 
engagement with its receptors CXCR1/2, is a well-known driver of the stemness properties of the 
highly tumorigenic and resistant to cancer therapy sub-populations of so-called cancer stem cells [61–
63], it is tempting to suggest that IL-8- or CXCR1/2-neutralizing antibodies might be therapeutically 
relevant for the clinical management of particular subsets of ER-positive/HER2-negative luminal 
breast carcinomas overexpressing the HER3 ligand HRG. In this regard, we do recognize that the 
main weakness of our study is the lack of experimental evidence supporting the antitumor activity 
of IL-8- or CXCR1/2-neutralizing antibodies in cultured and xenografted HRG-overexpressing/ER+ 
breast cancer cells. Furthermore, the therapeutic relevance of our findings certainly requires the 
analysis of breast cancer series to validate the driving role of HRG in endocrine therapy resistance. 
Only then will we be able to support the prognostic and therapeutic relevance of the HRG/IL-8/ER 
cross-talk in breast cancer patients. 
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4. Materials and Methods 
4.1. Materials 
Phenol red-free Improved Minimal Essential Medium (IMEM) was from Biofluids, Inc. 
(Rockville, MD, USA). Dextran-coated charcoal-treated bovine serum (CCS) was from Biosource 
International (Camarillo, CA, USA). RayBioTM C-series (C7) Human Cytokine Array was purchased 
from RayBiotech, Inc. (Norcross, GA, USA). E2 was from Sigma-Chemical Co. (St. Louis, MO, USA). 
The anti-human CXCL8/IL-8 monoclonal antibody (clone 6217)–a functional antibody capable of 
neutralizing CXCL8 bioactivity was from R&D Systems, Inc. (Minneapolis, MN, USA; Cat. # 
MAB208). 
4.2. Cell Lines and Culture Conditions 
The PCR products generated using the HRGβ2 cDNA accession number 183996 (full-length 
HRGβ2) or the structural deletion mutants (HRGβ2-M4 and HRGβ2-M1) were cloned into the 
retroviral expression vector pBABE-Puro using BamHI and EcoRI restriction sites. Retroviral 
constructs were transfected into a high efficiency transient amphotropic packaging system (TSA54 
cell line) with FuGENE reagent. Retrovirus-containing medium collected after 48 h was used to infect 
MCF-7 cells for 24 h in the presence of Polybrene (Sigma-Chemicals, St. Louis, MO, USA). Infected 
MCF-7 cells were grown for an additional 24 h in standard medium and stable cell lines (MCF-
7/pBABE, MCF-7/HRGβ2, MCF-7/HRGβ2-M4, and MCF-7/HRGβ2-M1) were selected and expanded 
in the presence of 2.5 μg/mL puromycin for 2 weeks. Expression levels of HRGβ2, HRGβ2-M4, and 
HRGβ2-M1 were assessed by RT-PCR using the Gene Amp Kit (Promega Corporation, Madison WI, 
USA). MCF-7 cells stably overexpressing HER2 (clone MCF-7/Her2-18), and their vector-transfected 
counterparts (MCF-7/neo) were kindly provided by Dr. Mien-Chie Hung (The University of Texas 
M.D. Anderson Cancer Center, Houston, TX, USA). 
4.3. Conditioned Medium 
To prepare a conditioned medium, cells were plated in 100 mm tissue-culture dishes until they 
reached 75–80% confluence. Cells were washed twice with serum-free IMEM and incubated 
overnight in serum-free IMEM. Cells were then cultured for 48 h in a low-serum (0.1%) medium. The 
supernatants were collected, centrifuged at 1,000 × g, aliquoted, and stored at −80 °C until testing. 
4.4. Cytokine Antibody Arrays 
Assays for cytokine antibody arrays were carried out as per the manufacturers’ instructions. 
Briefly, cytokine array membranes were blocked with 5% BSA/TBS (0.01 mol/L Tris-HCl pH 7.6/0.15 
mol/L NaCl) for 1 h. Membranes were then incubated with ~2 mL of conditioned media prepared 
from the different cell lines after normalization for equal amounts of protein. After extensive washing 
with TBS/0.1% v/v Tween 20 (3 times, 5 min each) and TBS (2 times, 5 min each) to remove unbound 
material, the membranes were incubated with a cocktail of biotin-labeled antibodies against different 
individual cytokines. The membranes were then washed and incubated with horseradish peroxidase 
(HRP)-conjugated streptavidin (2.5 pg/mL) for 1 h at room temperature. Unbound HRP-streptavidin 
was washed out with TBS/0.1% v/v Tween 20 and TBS. Signals were finally detected using the ECL 
system (Amersham, Arlington Heights, IL, USA). Densitometric values were quantified using Scion 
Imaging Software (Scion Corp., Frederick, MD, USA). 
4.5. IL-8 ELISA 
IL-8 levels were measured using a quantitative immunometric sandwich ELISA following the 
procedures recommended by the manufacturer (R&D Systems, Minneapolis, MN, USA). Triplicate 
cultures were tested for each experimental condition. 
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4.6. ER Transcriptional Activity 
Cells were propagated in E2-deprived (phenol red-free) IMEM with 5% CCS for 5 days before 
the onset of experiments. For experiments, the cells were seeded into 12-well plates at 1 × 105 
cells/well. Cells were transfected using the FuGENE 6 reagent (Roche Biochemicals, Indianapolis, IN, 
USA) with 1 g/well of the estrogen-responsive reporter, ERE-Luc, containing a Xenopus vitellogenin 
A2-derived ERE, along with 0.1 μg/well of the internal control plasmid pRL-CMV, used to correct for 
transfection efficiency. After 18 h, cells were washed and then incubated in fresh medium containing 
5% CCS, supplemented with E2 (10−9 mol/L), anti-IL-8 antibody (0.1, 0.5, 1, 5, and 10 μg/mL), 
combinations of these compounds as specified, and vehicles (v/v) alone. Approximately 24 h after 
treatments, Luciferase activity from cell extracts was measured using a Luciferase Assay System 
(Promega, Madison, WI, USA) on a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA). 
The magnitude of activation in ERE-Luciferase-transfected cells treated with the vehicle was 
determined after normalization to the activity of pRL-CMV and was defined as 1.0-fold. This control 
value was used to calculate the relative (fold) change in transcriptional activities of ERE-Luciferase-
transfected cells in response to treatments after normalization to pRL-CMV activity. All data were 
normalized as the ratio of raw light units to pRL-CMV units corrected for pRL-CMV activity, and 
were shown as the mean ± S.D. from 3 separate experiments (performed in triplicate). 
4.7. Statistical Analysis 
For all experiments, at least 3 independent experiments were performed with n≥3 replicate 
samples per experiment. Investigators were blinded to animal data allocation. Experiments were not 
randomized. Data were presented as mean ± S.D. Comparisons of means of ≥3 groups were 
performed by one-way ANOVA and Dunnett’s t-test for multiple comparisons using GraphPad 
Prism (GraphPad Software, San Diego, CA, USA). In all studies, p-values <0.05 and <0.005 were 
considered to be statistically significant (denoted as * and **, respectively). All statistical tests were 
two-sided. 
5. Conclusions 
Persistent promotion of HER2/HER3 signaling due to the overproduction of the HER3 ligand 
HRG suffices to upregulate IL-8 expression as part of the endocrine-resistant phenotype in ER-
positive/HER2-negative breast cancer cells. These findings might illuminate a potential clinical 
setting for IL8- or CXCR1/2-neutralizing antibodies in ER+ breast carcinomas overexpressing HRG. 
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/21/20/7737/s1. 
Figure S1: Cytokines map of the RayBio® Human Cytokine Antibody Array VII & 7.1. 
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